BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Belumosudil readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Belumosudil\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07726914-1886@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20270126
DTEND;VALUE=DATE:20270127
SUMMARY:Belumosudil: Phase 1 readout est. (NCT07726914)
DESCRIPTION:Belumosudil\, phase 1\, Graft-versus-Host Disease.\nStudy: Stud
 y to Compare the Plasma Concentration of Belumosudil Given as an Oral Susp
 ension and as a Tablet to Healthy Adult Male Participants\nEstimated prima
 ry completion: 26 January 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/belumosudil#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07726914
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06476132-1886@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Belumosudil: Phase 2 readout est. (NCT06476132)
DESCRIPTION:Belumosudil\, phase 2.\nStudy: Belumosudil to Block Chronic Lun
 g Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients\nEs
 timated primary completion: 30 May 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/belumosudil#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06476132
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05922761-1886@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Belumosudil: Phase 2 readout est. (NCT05922761)
DESCRIPTION:Belumosudil\, phase 2\, Graft-versus-Host Disease.\nStudy: BElu
 mosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)\nEstimated
  primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/belumosudil#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05922761
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07135973-1886@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Belumosudil: Phase 4 readout est. (NCT07135973)
DESCRIPTION:Belumosudil\, phase 4\, Graft-versus-Host Disease.\nStudy: A St
 udy to Investigate Safety of Belumosudil in Participants Aged 12 Years and
  Above\, With Chronic Graft-versus-host Disease (cGVHD)\nEstimated primary
  completion: 30 August 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/belumosudil#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07135973
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06105554-1886@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Belumosudil: Phase 1/2 readout est. (NCT06105554)
DESCRIPTION:Belumosudil\, phase 1/2.\nStudy: Phase I/II Open Label Study of
  Belumosudil Mesylate Alone\, and in Combination With Dexamethasone\, in P
 atients With Relapsed/Refractory Multiple Myeloma\nEstimated primary compl
 etion: 31 August 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/belumosudil#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06105554
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04643002-1886@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20270913
DTEND;VALUE=DATE:20270914
SUMMARY:Belumosudil: Phase 1/2 readout est. (NCT04643002)
DESCRIPTION:Belumosudil\, phase 1/2.\nStudy: Isatuximab in Combination With
  Novel Agents in RRMM - Master Protocol\nEstimated primary completion: 13 
 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/belum
 osudil#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04643002
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06751602-1886@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Belumosudil: Phase 2 readout est. (NCT06751602)
DESCRIPTION:Belumosudil\, phase 2.\nStudy: Belumosudil for Abrogation of In
 terstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation\n
 Estimated primary completion: December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/belumosudil#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06751602
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07127926-1886@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Belumosudil: Phase 1 readout est. (NCT07127926)
DESCRIPTION:Belumosudil\, phase 1\, Graft-versus-Host Disease.\nStudy: Eval
 uation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics i
 n Patients Suffering From Chronic GvHD\nEstimated primary completion: 31 D
 ecember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/belumos
 udil#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07127926
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05996627-1886@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Belumosudil: Phase 2 readout est. (NCT05996627)
DESCRIPTION:Belumosudil\, phase 2\, Graft-versus-Host Disease.\nStudy: Belu
 mosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versu
 s Host Disease\nEstimated primary completion: 30 April 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/belumosudil#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05996627
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07484113-1886@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Belumosudil: Phase 1 readout est. (NCT07484113)
DESCRIPTION:Belumosudil\, phase 1.\nStudy: IL6-receptor Inhibitor Iwith Bel
 umosudil for the Treatment of Belumosudil-refractory cGVHD\nEstimated prim
 ary completion: May 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/belumosudil#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07484113
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05806749-1886@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Belumosudil: Phase 1 readout est. (NCT05806749)
DESCRIPTION:Belumosudil\, phase 1.\nStudy: Immunological Tolerance in Patie
 nts With Mismatched Kidney Transplants\nEstimated primary completion: Augu
 st 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/belumosudil#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0580
 6749
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07116031-1886@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20280925
DTEND;VALUE=DATE:20280926
SUMMARY:Belumosudil: Phase 2 readout est. (NCT07116031)
DESCRIPTION:Belumosudil\, phase 2\, Graft-versus-Host Disease.\nStudy: A St
 udy of Belumosudil in Children With Chronic Graft Versus Host Disease (sch
 oolROCK)\nEstimated primary completion: 25 September 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/belumosudil#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07116031
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06143891-1886@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20280929
DTEND;VALUE=DATE:20280930
SUMMARY:Belumosudil: Phase 3 readout est. (NCT06143891)
DESCRIPTION:Belumosudil\, phase 3\, Graft-versus-Host Disease.\nStudy: A St
 udy to Test an Oral Medicine\, Belumosudil\, in Combination With Corticost
 eroids in Participants at Least 12 Years of Age With Newly Diagnosed Chron
 ic Graft Versus Host Disease.\nEstimated primary completion: 29 September 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/belumosudil#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0614389
 1
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06082037-1886@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20290129
DTEND;VALUE=DATE:20290130
SUMMARY:Belumosudil: Phase 3 readout est. (NCT06082037)
DESCRIPTION:Belumosudil\, phase 3.\nStudy: A Study to Test How Effective Be
 lumosudil Tablets Are for Treating Adult Participants With Chronic Lung Al
 lograft Dysfunction\nEstimated primary completion: 29 January 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/belumosudil#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06082037
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07006506-1886@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20290521
DTEND;VALUE=DATE:20290522
SUMMARY:Belumosudil: Phase 2 readout est. (NCT07006506)
DESCRIPTION:Belumosudil\, phase 2\, Graft-versus-Host Disease.\nStudy: A St
 udy of Belumosudil in People at Risk of Developing Graft-Versus-Host Disea
 se After a Stem Cell Transplant\nEstimated primary completion: 21 May 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/belumosudil#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07006506
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07771439-1886@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20290914
DTEND;VALUE=DATE:20290915
SUMMARY:Belumosudil: Phase 3 readout est. (NCT07771439)
DESCRIPTION:Belumosudil\, phase 3\, Graft-versus-Host Disease.\nStudy: A St
 udy to Investigate the Efficacy and Safety of Belumosudil Compared With Be
 st Available Therapy in Participants Aged 12 Years or Older With Chronic G
 raft-versus-host Disease\nEstimated primary completion: 14 September 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/belumosudil#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07771439
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07643025-1886@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Belumosudil: Phase 2 readout est. (NCT07643025)
DESCRIPTION:Belumosudil\, phase 2\, Graft-versus-Host Disease.\nStudy: Belu
 mosudil With Ruxolitnib as Third Line Therapy for Chronic Graft Versus Hos
 t Disease (cGvHD)\nEstimated primary completion: November 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/belumosudil#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07643025
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07794514-1886@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20300401
DTEND;VALUE=DATE:20300402
SUMMARY:Belumosudil: Phase na readout est. (NCT07794514)
DESCRIPTION:Belumosudil\, phase na.\nStudy: Belumosudil Versus Ruxolitinib 
 for Steroid-Refractory or Breakthrough Hepatic cGVHD\nEstimated primary co
 mpletion: 1 April 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/belumosudil#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07794514
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
